Table 1 Baseline characteristics of the 6,055 participants.
Age (years) | 69.3 (±8.2) |
Female sex | 3,461 (57.2) |
Systolic blood pressure (mmHg) | 143 (±21) |
Diastolic blood pressure (mmHg) | 77 (±11) |
Antihypertensive medication | 2,017 (35.0) |
Pre-diabetes | 1,663 (28.1) |
Diabetes | 744 (12.6) |
Serum cholesterol (mmol/L) | 5.82 (±0.98) |
Serum HDL cholesterol (mmol/L) | 1.39 (±0.39) |
Serum triglycerides (mmol/L; median, IQR) | 1.35 (1.03–1.81) |
Lipid-lowering medication | 746 (12.8) |
Smoking | |
Former | 2,958 (49.3) |
Current | 1,032 (17.2) |
Creatinine (mg/dL) | 0.89 (±0.21) |
Body-mass index (kg/m2) | 26.9 (±4.0) |
History of cardiovascular disease | 283 (4.7) |
Anti-thrombotic medication | 1,135 (18.7) |
APOE genotype | |
3/3 | 3,389 (58.1) |
ε2/2 or ε2/3 | 821 (14.1) |
ε2/4 or ε3/4, ε4/4 | 1,627 (27.9) |
Von Willebrand factor (IU/mL; median, IQR) | 1.20 (0.93–1.60) |
ADAMTS13 (%) | 91.5 (±17.7) |
Fibrinogen (g/L; median, IQR) | 3.8 (3.3–4.4) |
C-reactive protein (mg/mL; median, IQR) | 1.8 (0.7–3.7) |
Blood type O | 2348 (45.6) |
